Skip to content
Vectron Biosolutions AS logo — Unique solutions to unique problems

Vectron Biosolutions AS

Unique solutions to unique problems

Founded 2008 11 employees Series A Total: $2.70M Biotechnology, Health Care +1

General Information

Company Name Vectron Biosolutions AS
Founded Year 2008
Founders / Decision Makers
Team member
Employees 11
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Vectron Biosolutions AS. To contact Vectron Biosolutions AS, visit vectronbiosolutions.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vectron Biosolutions AS compare?

A PDF of Vectron Biosolutions AS and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vectron Biosolutions AS soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vectron Biosolutions AS

Vectron Biosolutions AS is a biotechnology startup with the slogan "Unique solutions to unique problems." Established in 2008, Vectron specializes in developing robust and cost-efficient microbial protein production processes. Their proprietary portfolio of expression technologies enables the development of bacterial strains that produce specific proteins at optimum titers and quality.

The most recent milestone for Vectron Biosolutions is a $2.70M Series A investment led by Dynamk Capital on 17 June 2021. This injection of capital underscores investor confidence in the company's innovative approach and ability to address critical challenges within the health care and life sciences sectors.

Business keywords: Microbial protein production, Expression technologies, Bacterial strains, Recombinant protein production, Vector technologies, CDMO, Gene expression, Protein production, Molecular engineering, Life science research

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $2.70M 1
Dynamk Capital
17 Jun 2021

Vectron Biosolutions AS Alternatives & Competitors

View All Alternatives
Vectron Biosolutions AS vs
KACTUS
KACTUS United States

Design and manufacturing recombinant proteins: antigens for antibody drug discovery, MHC complexes,...

Series B
18 employees
Biotechnology, Health Care
Vectron Biosolutions AS vs

Committed to Lifescience

10 employees
Biotechnology, Life Sciences
Vectron Biosolutions AS vs

As full service provider for the life science industry, we have a clear mission: Accelerating your i...

22 employees
Biotechnology, Life Sciences

FAQ About Vectron Biosolutions AS

Unique solutions to unique problems
Vectron Biosolutions AS was founded in 2008.
Vectron Biosolutions AS operates in Biotechnology, Health Care and Life Sciences. Its work centres on Microbial protein production, Expression technologies, Bacterial strains and Recombinant protein production.
Vectron Biosolutions AS has approximately 11 employees.
Vectron Biosolutions AS has completed 1 funding round, raising a total of $2.70M. The latest funding stage is Series A.
Top alternatives and competitors to Vectron Biosolutions AS include KACTUS, Pepmic Co., Ltd, trenzyme GmbH, Wuhan Healthgen Biotechnology Corp., GeneCust S.A.S.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vectron Biosolutions AS and KACTUS are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vectron Biosolutions AS, https://bouncewatch.com/company/vectron-biosolutions-as, updated 24 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout